Table 3.
Association between RANKL ImmunohistoChemistry Expression in Osteosarcoma with the Clinicopathological Characteristics Using Pearson Chi-Square (n=100).
| Variables | RANKL negative n (%) |
RANKL positive n (%) |
p value |
|---|---|---|---|
| Clinicopathological characteristics | |||
| Age group (year) | |||
| < 40 | 16 (17.4) | 76 (82.6) | 0.632† |
| ≥ 40 | 2 (25) | 6 (75) | |
| Gender | 0.774 | ||
| Male | 13 (21) | 49 (79) | |
| Female | 5 (13.2) | 33 (86.8) | |
| Family history with osteosarcoma (n=30)* | 0.48† | ||
| No | 5 (17.2) | 24 (82.8) | |
| Yes | 0 (0) | 1 (100) | |
| Presentation (n=74)* | 0.342† | ||
| Bone pain | 6 (24) | 19 (76) | |
| Swelling | 7 (14.3) | 42 (85.7) | |
| Tumour volume (n=75)* | 0.96† | ||
| < 150 ml | 5 (21.7) | 18 (78.3) | |
| ≥ 150 ml | 9 (17.3) | 43 (82.7) | |
| Tumour site (n=97)* | |||
| Femur | 9 (20) | 36 (80) | 0.143† |
| Tibia | 3 (10.7) | 25 (89.3) | |
| Humerus | 0 (0) | 7 (100) | |
| Maxillofacial | 0 (0) | 2 (100) | |
| Pelvic | 3 (60) | 2 (40) | |
| Others | 2 (20) | 8 (80) | |
| Stage of disease (Enneking) (n=76)* | |||
| IA | - | - | 0.18† |
| IB | - | - | |
| IIA | 0 (0) | 2 (100) | |
| IIB | 11 (21.6) | 40 (78.4) | |
| III | 4 (17.4) | 19 (82.6) | |
| Grade | |||
| Low | 1 (50) | 1 (50) | 0.329† |
| High | 17 (17.3) | 81 (82.7) | |
| Metastatic event (n=94)* | 0.36 | ||
| No | 7 (18.4) | 31 (81.6) | |
| Yes | 9 (16.1) | 47 (83.9) | |
| Surgery (n=88)* | 0.064† | ||
| No | 0 (0) | 15 (100) | |
| Yes | 15 (20.5) | 58 (79.5) | |
| Chemotherapy (n=89)* | 1.000† | ||
| No | 4 (16.7) | 20 (83.3) | |
| Yes | 12 (18.5) | 53 (81.5) | |
| Response to chemotherapy (n=43*) | 0.69† | ||
| Non-Responder | 10 (32.3) | 21 (67.7) | |
| Responder | 1 (8.3) | 11 (91.7) | |
| Recurrence (n=96)* | 1.000† | ||
| No | 15 (17.4) | 71 (82.6) | |
| Yes | 1 (10) | 9 (90) | |
*, Not all the patients had complete clinicopathological data; †, Fisher's Exact Test.